Dose-Dependent Gastrointestinal Absorption of 5-Fluorouracil in Rats *in Vivo*

Hiroaki YUASA,* Kenji MATSUDA, Jian GU, Emiko SUZUKI, Itsuko YOKOUCHI, and Jun WATANABE

Faculty of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467, Japan.
Received April 25, 1996; accepted July 29, 1996

Dose-dependent gastrointestinal absorption of 5-fluorouracil (5-FU) was kinetically evaluated in rats *in vivo* by analyzing gastrointestinal disposition after oral administration, where a linear model assuming first-order gastric emptying followed by first-order intestinal absorption was fitted to remaining fraction *versus* time profiles for the stomach and small intestine to estimate the rate constants of gastric emptying (k_g) and intestinal absorption (k_a). With an increase in dose from 1.5 nmol/rat (low dose) to 15 μ mol/rat (high dose), the k_a decreased from 5.95 to 0.55 min⁻¹, suggesting the involvement of carrier-mediated transport. This study is the first to demonstrate the dose-dependent gastrointestinal absorption of 5-FU *in vivo*, though it has long been suggested *in situ* and *in vitro*. Meanwhile, at both the low and high doses, the k_g values, which were unaffected by dose (0.069 and 0.082 min⁻¹, respectively, for the low and high doses), were smaller than the k_a values by an order of magnitude or more and the recovery of 5-FU was negligible, compared with that of inulin (a nonabsorbable marker), in the most distal segment of ileum. These results suggest that, regardless of dose, 5-FU is highly absorbable in a gastric emptying-limited manner. Thus, well-publicized bioavailability problems (low and erratic) of 5-FU may be attributable to extensive and variable first-pass metabolism rather than poor and variable gastrointestinal absorption.

Key words intestinal absorption; 5-fluorouracil; dose dependency; rat; carrier-mediated transport; gastrointestinal disposition analysis

5-Fluorouracil (5-FU) has been widely used in the treatment of solid tumors, such as breast and gastrointestinal cancers, and is clinically available in oral dosage forms.¹⁾ However, the bioavailability of orally administered 5-FU in humans is reportedly low and erratic (0–74%).²⁾ Carrier-mediated transport, which can cause dose-dependent variability in gastrointestinal absorption (absorption rate constant and fraction absorbed), has long been suggested to be involved in the intestinal absorption of 5-FU and suspected to be at least in part a source of the problems.^{3–12)} However, this remains unconfirmed with little information about 5-FU absorption *in vivo*.

In an effort to determine the sources of the bioavailability problems of 5-FU, we kinetically evaluated the dose-dependent gastrointestinal absorption of the drug in rats *in vivo* by gastrointestinal disposition analysis.¹³⁾

MATERIALS AND METHODS

Chemicals [³H]5-FU (555.0 GBq/mmol), [¹⁴C]inulin (96.0 MBq/g) and Scintisol, a scintillation cocktail, were purchased from Dupont-NEN Co. (Boston, MA, U.S.A.). Soluene-350, a tissue solubilizer, was purchased from Packard Instrument Co. Inc. (Meriden, CT, U.S.A.). Unlabeled 5-FU (Wako Pure Chemical Industries, Ltd., Osaka, Japan) was commercially obtained. All other reagents were of analytical grade and commercially obtained.

Dosing Solutions The dosing solutions, containing 0.01 (low dose) or 10 (high dose) mM 5-FU with a trace amount (404 kBq/0.728 nmol/ml) of [³H]5-FU and a trace amount (33.7 kBq/0.4 mg/ml) of [¹⁴C]inulin, a nonabsorbable marker, were prepared in saline (0.9% NaCl solution).

Gastrointestinal Disposition Experiments Male Wistar

rats, weighing about 300 g and fasted overnight, were given an oral dose of 1.5 nmol/0.15 ml/rat (low dose) or 15 μ mol/1.5 ml/rat (high dose) of 5-FU using a gastric tube. The rats were then left free in a metabolic cage at the ambient temperature of 25 °C, and sacrificed at 5, 10, 20, 40, or 60 min after dosing by puncturing the heart under ether anesthesia to sample the gastrointestinal contents and tissues of stomach, duodenum and three equal lengths of small intestinal segments (jejunum, midgut and ileum) as described in our previous report.¹³⁾ After adding the appropriate amount of saline, the gastrointestinal contents and tissues were homogenized, and a portion of each homogenized sample was solubilized for the determination of radioactivity as also described previously,¹³⁾ using Soluene-350 (1 ml) as a tissue solubilizer and Scintisol EX-H (5 ml) as a scintillation cocktail.

The remaining fraction (*FR*) of 5-FU in the gastrointestinal tract of each segment was estimated to be the sum of that in the contents sample and that in the fluid adhering to the tissue. The volume of adherent fluid was estimated from the amount of inulin associated with the tissue.

As discussed earlier,¹³⁾ assuming that the apparent intestinal membrane permeability clearance (CL_{app}) and the average intestinal lumen volume for unit length (V_{av}) are constant along the small intestine, the intestinal absorption can be described as a first-order process with a rate constant of k_a . Therefore, further assuming that the gastric emptying is described by a first-order rate constant of k_g , and that the gastric absorption and the transfer from the small intestine to the large intestine are negligible, the same model equation as those for a linear compartment model consisting of the stomach and small intestine compartments can be used to describe the remaining fraction of dose in the stomach (FR_s) and small

* To whom correspondence should be addressed.

intestine (FR_{si}) as follows:

$$FR_s = e^{-k_e t} \quad (1)$$

$$FR_{si} = (e^{-k_a t} - e^{-k_e t}) / (1 - k_a/k_e) \quad (2)$$

Equations 1 and 2 were simultaneously fitted to FR_s and FR_{si} data, which were corrected for (normalized by) the total fraction of inulin recovered from the gastrointestinal tract, for 5-FU to estimate k_a and k_e , using a nonlinear regression program, PCNONLIN (Scientific Consulting Inc., Apex, NC), and weighted according to the reciprocal of the variance.

Pharmacokinetic Analysis of Plasma Concentration

Data Male Wistar rats, weighing about 300 g and fasted overnight, were cannulated in the right jugular vein under light ether anesthesia. After regaining consciousness and allowing a recovery period of 1 h, each rat was orally (through a gastric tube) or intravenously (through the cannula) given a low dose (1.5 nmol/0.15 ml/rat) of [3H]5-FU, and left free in a metabolic cage at an ambient temperature of 25 °C; 100 μ l of blood was taken periodically through the cannula and placed in a centrifuge tube containing 5 units of heparin and centrifuged for 3 min with a Microfuge E (Beckman Instruments, Inc., Palo Alto, CA, U.S.A.) to obtain plasma. The plasma (20 μ l) was placed in a counting vial to which was added 3 ml Scintisol, to determine the radioactivity with a liquid scintillation counter (LSC-1000, Aloka Co., Tokyo, Japan).

Plasma concentration (C) versus time (t) profiles of 5-FU were analyzed by a one-compartment model with first-order absorption, where the plasma concentrations after oral and intravenous administration are described by Eqs. 3 and 4, respectively,

$$C = A \cdot e^{-k_{el} t} \quad (3)$$

$$C = \frac{A \cdot F_a \cdot k'_a}{(k'_a - k_{el})} \cdot (e^{-k_{el} t} - e^{-k'_a t}) \quad (4)$$

where k_{el} , k'_a and F_a are the elimination rate constant, the apparent absorption rate constant and the fraction absorbed, respectively, and A is a constant. The values of A and k_{el} were estimated by fitting Eq. 3 to the concentration versus time profiles after intravenous administration using a nonlinear regression program, PCNONLIN. With the values of A and k_{el} fixed, the values of k'_a and F_a were estimated by fitting Eq. 4 to the concentration versus time profiles after oral administration.

Gastric Absorption Male Wistar rats, weighing about 300 g and fasted overnight, were anesthetized with urethane (1.25 g/kg, i.p.), and a low dose of 5-FU was administered to the stomach, which was ligated at the cardia and the pylorus. 5-FU remaining in the gastric contents was determined 60 min after administration as described previously.¹⁴⁾

Biliary Excretion Male Wistar rats, weighing about 300 g and without fasting, were anesthetized with urethane (1.25 g/kg, i.p.). The common bile duct was cannulated with PE-10 tubing, and bile was collected for 60 min after injection (0.5 ml) of [3H]5-FU solution (0.01 mM), which was prepared in phosphate buffer (20.1 mM Na_2HPO_4 ·

12H₂O, 47.0 mM KH_2PO_4 , 101.0 mM NaCl, pH 6.4) and added with [^{14}C]inulin as a nonabsorbable marker, into a 5-cm intestinal (midgut) loop. Fifty microliters of the bile sample was placed in a counting vial, to which 5 ml of Scintisol was added for radioactivity determination. At the end of experiments, 5-FU remaining in the intestinal lumen was also determined to evaluate 5-FU absorption (disappearance) from the loop.^{15,16)}

Stability in the Gastrointestinal Contents Male Wistar rats, weighing about 300 g and fasted overnight, were sacrificed by puncturing the heart under ether anesthesia. Gastric and midgut contents were collected and added with citrate buffer (30.0 mM HCl, 32.8 mM citric acid, 60.0 mM NaOH, 71.8 mM NaCl, pH 2.0) and phosphate buffer (pH 6.4), respectively, to make 20% homogenates. [3H]5-FU solutions (0.001 mM or 555 kBq/ml) were also prepared in the buffers of pH 2.0 and 6.4. The experiments were initiated by adding 0.65 ml of a 5-FU solution to 0.65 ml of a homogenate in a centrifuge tube (0.5 μ M [3H]5-FU in 10% homogenate). After 60 min of incubation at 37 °C, the mixture was centrifuged at 4 °C and 15000 g for 10 min with a MRX-150 centrifuge (Tomy Seiko Co., Tokyo, Japan), and the supernatant was filtrated with a disposable filter (DISMIC-25CS 0.45 μ m, ADVANTEC Co., Tokyo, Japan). The filtrate was analyzed with a HPLC system (LC-10A, Shimadzu Co., Kyoto, Japan) equipped with a radio analyzer (RLC-700, Aloka Co., Tokyo, Japan) under previously reported conditions¹⁷⁾ with slight modifications for the column (Wakopak, Wakosil 10C18-200 4.0 mm i.d. $\times$ 250 mm, Wako Pure Chemical Industries, Ltd., Tokyo, Japan) and injection volume (200 μ l).

RESULTS

Gastrointestinal Distribution Profiles The recovery of 5-FU was, regardless of dose and sampling time, comparable with that of inulin in the stomach, but far lower than that of inulin in the small intestine (Fig. 1). The gastric absorption of 5-FU was, as estimated in the closed stomach of rats under urethane anesthesia, $18 \pm 2\%$ (mean $\pm$ S.E.; $n = 3$) in 60 min, giving an absorption rate constant of $0.0034 \pm 0.0004 \text{ min}^{-1}$, which was negligible compared with 20 to 30 times larger gastric emptying rate constants described later. 5-FU was quite stable in gastric and intestinal (midgut) contents, where the fractions recovered were 96 and 99%, respectively, after 60 min of incubation in 10% homogenate at the 5-FU concentration of 0.5 μ M. These results suggest that 5-FU is, regardless of dose, rapidly absorbed in the small intestine without gastric absorption or degradation in the gastrointestinal tract. The total recovery of inulin from the stomach and small intestine was about 100% throughout the experimental period of 60 min, assuring that its distribution was restricted within the region of the gastrointestinal tract and transit from the small intestine to the large intestine can be neglected. It was also confirmed that the biliary excretion of 5-FU was negligible: only $0.37 \pm 0.08\%$ (mean $\pm$ S.E.; $n = 3$) of dose was excreted in 60 min after administration to the closed midgut loop, as estimated in rats under urethane anesthesia, where the absorption

Fig. 1. Gastrointestinal Disposition of [^3H]5-FU and Coadministered [^{14}C]Inulin after Oral Administration of Varied Doses of 5-FU in Rats. Results are represented as the mean ($n=4$). Panels 1a (5-FU) and 1b (inulin) are for the low dose (1.5 nmol/rat), and panels 2a (5-FU) and 2b (inulin) are for the high dose (15 $\mu\text{mol/rat}$). Keys: S, stomach; D, duodenum; J, jejunum; M, midgut; I, ileum.

from the loop was almost complete (98%). All these results meet the assumptions in the model analysis incorporated with only gastric emptying and intestinal absorption (Eqs. 1 and 2).

Kinetic Analysis of Gastrointestinal Disposition The remaining fractions of 5-FU from all intestinal segments were summed for each time to obtain the total fraction of the drug remaining in the small intestine for model analysis. The profiles of remaining 5-FU *versus* time for stomach and small intestine were successfully described by the model (Eqs. 1 and 2) up to 20 min (Fig. 2), though the model appeared to fit the data somewhat poorly for the low dose. The parameters are summarized in Table 1. After 20 min, the remaining fractions of 5-FU in the small intestine were independent of dose and time, and could not be explained by the proposed model. Because the plasma concentrations of total radioactivity were also independent of time after 20 min as shown in Fig. 3 for the low dose, the luminal radioactivity may be equilibrated with the plasma radioactivity, representing not only 5-FU but also its metabolites (dihydro-5-fluorouracil, 5-fluoroureaidopropionic acid and α -fluoro- β -alanine).¹⁾

While the gastric emptying was not affected by dose, intestinal 5-FU absorption was reduced with dose, as reflected by larger fractions remaining in the small intestine and a smaller k_a value for the higher dose. Because the k_a value was associated with a large S.E. for the low dose, additional simulations were performed for k_a values of 1 and 10 min^{-1} to further confirm the dose dependency in k_a . The data points for small intestine were within the range of the simulation lines for the k_a values of 1 and 10 min^{-1} , suggesting that k_a for the low dose would not

Fig. 2. Remaining [^3H]5-FU *versus* Time Profiles for the Stomach and Small Intestine after Oral Administration of Varied Doses of 5-FU in Rats.

Results are represented as the mean $\pm$ S.E. ($n=4$). The solid lines represent the computer-fitted profiles up to 20 min. For the data after 20 min, where the model was not applicable, each series of data were connected by broken lines for clarity. Keys: $\circ$ (stomach) and $\bullet$ (small intestine) for low dose (1.5 nmol/rat), and $\square$ (stomach) and $\blacksquare$ (small intestine) for high dose (15 $\mu\text{mol/rat}$). The lines of - - - and are simulation lines using k_a of 1 and 10 min^{-1} , respectively, for the low dose.

Table 1. Kinetic Parameters of Gastrointestinal Disposition of 5-FU in Rats

Dose	k_g (min^{-1})	k_a (min^{-1})	CL_{app} ($\mu\text{l/min/cm}$)
1.5 nmol/rat	0.069 ± 0.008	5.95 ± 27.53	143
15 $\mu\text{mol/rat}$	0.082 ± 0.010	0.55 ± 0.29	13

Values of k_g (gastric emptying rate constant) and k_a (intestinal absorption rate constant) are represented as the computer-fitted parameter with S.E.; CL_{app} , apparent membrane permeability clearance as $k_a \cdot V_{av}$, where V_{av} is the average intestinal lumen volume (24 $\mu\text{l/cm}$).¹³⁾

Fig. 3. Plasma Concentrations of Radioactivity after Intravenous and Oral Administration of [^3H]5-FU in Rats

Results are represented as the mean $\pm$ S.E. ($n=3$). The solid lines represent the computer-fitted profiles. A low dose of 5-FU (1.5 nmol/rat) was administered intravenously ($\circ$) and orally ($\bullet$).

be smaller than 1 min^{-1} and at least 2 times larger than that for the high dose (0.55 min^{-1}). This is the first demonstration of dose dependency in intestinal 5-FU absorption *in vivo*, though carrier-mediated transport has long been suggested *in situ* and *in vitro*.³⁻¹²⁾

The k_a values were larger than k_g values by an order of magnitude or more at both the low and high doses, suggesting that the gastrointestinal absorption of 5-FU is gastric emptying-limited regardless of dose. It should also be noted that, for both the low and high doses, the recovery of 5-FU from the most distal segment of ileum was negligibly lower than that of inulin (a nonabsorbable marker), as observed at 40 and 60 min (Fig. 1). Thus 5-FU was strongly suggested to be rapidly and completely absorbed regardless of dose.

Pharmacokinetic Analysis of Plasma Concentration To further confirm the gastric emptying-limited absorption of 5-FU, the plasma concentrations of total radioactivity for the low dose were analyzed. Although these concentrations, presumably representing 5-FU and its metabolites,¹⁾ were maintained at a quasi-steady state after 20 min for both intravenous and oral administration, the initial phase of concentrations up to 10 min was successfully described by the one-compartment model with first-order absorption (Eqs. 3 and 4). The kinetic parameters (mean $\pm$ S.E.; $n=3$) were obtained as follows: $A=0.457 \pm 0.033\%$ of dose/ml, $k_{el}=0.0649 \pm 0.0031 \text{ min}^{-1}$, $k'_a=0.041 \pm 0.012 \text{ min}^{-1}$ and $F_a=1.00 \pm 0.0001$. The k'_a was comparable with the k_g of 0.069 min^{-1} . Although k'_a may be modified by the potential involvement of first-pass metabolism, the appearance rate of [^3H]5-FU-derived radioactivity in plasma should not exceed the absorption (disappearance) rate of [^3H]5-FU from the gastrointestinal lumen. Thus this result suggests that 5-FU absorption is rapid enough to be gastric emptying-limited.

DISCUSSION

With the estimate of the average intestinal lumen volume (V_{av}), intestinal membrane permeability clearance (CL_{app}) can be estimated as the product of k_a and V_{av} .^{13,18)} Although dosing volume was larger for the high dose (1.5 ml/rat or 5 ml/kg) than the low dose (0.15 ml/rat or

0.5 ml/kg), our earlier studies showed that V_{av} of $24 \mu\text{l}/\text{cm}$ in fasted rats is not affected by dosing volume up to 5 ml/kg. Using the predetermined V_{av} value, CL_{app} values were estimated and listed in Table 1.

The intestinal carrier-mediated transport of 5-FU has been extensively characterized *in situ* and *in vitro*,³⁻¹²⁾ where, with the Michaelis constant of 20 to $100 \mu\text{M}$, the membrane permeability clearance is maximized (30 to $70 \mu\text{l}/\text{min}/\text{cm}$) at concentrations below $10 \mu\text{M}$ with carrier-mediated transport predominant, and minimized (2 to $6 \mu\text{l}/\text{min}/\text{cm}$) at concentrations above 1 mM with passive transport predominant.^{11,12)} On the other hand, 5-FU concentrations in the dosing solutions in this study were 0.01 and 10 mM, respectively, at the low and high doses, and can be lower in the intestinal lumen because of dilution by luminal fluid and absorption. For the low dose, luminal 5-FU concentrations should be lower than $10 \mu\text{M}$, suggesting that carrier-mediated transport would be predominant. For the high dose, since 5 to 10% of dose (15 $\mu\text{mol}/\text{rat}$) was distributed in the duodenum to midgut region, of which luminal volume is about 1 ml,¹³⁾ luminal 5-FU concentrations would be comparable with or higher than 1 mM, suggesting that passive transport would be predominant. Thus it seems reasonable that CL_{app} at the low dose is an order of magnitude larger than that at the high dose, in agreement with results *in vitro* and *in situ*. However, CL_{app} values *in vivo* are an order of magnitude larger than those for corresponding conditions *in situ* and *in vitro* (30 to 70 and 2 to $6 \mu\text{l}/\text{min}/\text{cm}$, respectively, for low and high concentrations). This remains unexplained and is a subject for future investigation.

As suggested for D-xylose absorption, which is intestinal absorption-limited,^{18,19)} the rate and extent of intestinal absorption by passive transport is comparable between rats and humans. Gastric emptying rate constants reported in humans ($0.02\text{--}0.2 \text{ min}^{-1}$)²⁰⁾ are, although variable, also comparable with those in rats in this study (Table 1), suggesting that the two species are comparable for the rate limiting process in the gastrointestinal absorption (gastric emptying or intestinal absorption). Since 5-FU was suggested to be rapidly and completely absorbed even at the high dose, where passive transport is presumably predominant, the same is expected in humans at high doses and also at low doses, where its absorption can be more efficient. Thus, the present study successfully demonstrated dose dependency in intestinal 5-FU absorption in rats *in vivo*, but also suggested that the gastrointestinal 5-FU absorption can be practically independent of dose, being completely absorbed in a gastric emptying-limited manner in rats, and also in humans. The bioavailability problems (low and erratic) of 5-FU may be attributable to extensive and variable first-pass metabolism rather than to poor and variable absorption.

Acknowledgment This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

REFERENCES

- 1) Diasio R. B., Harris B. E., *Clin. Pharmacokinet.*, **16**, 215—237 (1989).
- 2) Christophidis N., Vajda F. J. E., Lucas I., Drummer O., Moon W. J., Louis W. J., *Clin. Pharmacokinet.*, **3**, 330—336 (1978).
- 3) Schanker L. S., Tocco D. J., *J. Pharmacol. Exp. Ther.*, **128**, 115—121 (1960).
- 4) Schanker L. S., Jeffrey J. J., *Nature* (London), **190**, 727—728 (1961).
- 5) Schanker L. S., Jeffrey J. J., *Biochem. Pharmacol.*, **11**, 961—966 (1962).
- 6) Schanker L. S., Tocco D. J., *Biochim. Biophys. Acta*, **56**, 469—473 (1962).
- 7) Muranishi S., Yoshikawa H., Sezaki H., *J. Pharmacobio-Dyn.*, **2**, 286—294 (1979).
- 8) Sasaki H., Nakamura J., Konishi R., Shibasaki J., *Chem. Pharm. Bull.*, **34**, 4265—4272 (1986).
- 9) Bronk J. R., Hastewell J. G., *J. Physiol.* (London), **382**, 475—488 (1987).
- 10) Smith P., Mirabelli C., Fondacaro J., Ryan F., Dent J., *Pharm. Res.*, **5**, 598—603 (1988).
- 11) Yuasa H., Matsuda K., Watanabe J., *Biol. Pharm. Bull.*, **18**, 747—752 (1995).
- 12) Yuasa H., Matsuhisa E., Watanabe J., *Biol. Pharm. Bull.*, **19**, 94—99 (1996).
- 13) Yuasa H., Numata W., Ozeki S., Watanabe J., *J. Pharm. Sci.*, **84**, 476—481 (1995).
- 14) Yuasa H., Iga T., Hanano M., Watanabe J., *J. Pharmacobio-Dyn.*, **12**, 264—271 (1989).
- 15) Yuasa H., Kuno C., Watanabe J., *J. Pharm. Pharmacol.*, in press.
- 16) Yuasa H., Sekiya M., Ozeki S., Watanabe J., *Biol. Pharm. Bull.*, **17**, 756—758 (1994).
- 17) Watanabe J., Hayashi Y., Iwamoto K., Ozeki S., *Chem. Pharm. Bull.*, **33**, 1187—1194 (1985).
- 18) Yuasa H., Kawanishi K., Watanabe J., *J. Pharm. Pharmacol.*, **47**, 576—580 (1995).
- 19) Yuasa H., Kawanishi K., Watanabe J., *J. Pharm. Pharmacol.*, **47**, 373—378 (1995).
- 20) Oberle R. L., Chen T.-S., Lloyd C., Barnett J. L., Owyang C., Meyer J., Amidon G. L., *Gastroenterology*, **99**, 1275—1282 (1990).